Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03212027
Other study ID # 2016SF-211
Secondary ID
Status Not yet recruiting
Phase N/A
First received July 6, 2017
Last updated July 13, 2017
Start date July 31, 2017
Est. completion date May 1, 2018

Study information

Verified date July 2017
Source Tang-Du Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this study is to analyze aquaporins expression of thymic epithelial tumors and to compare them with apparent diffusion coefficient(ADC) from ultra-high b-values, and to test a possibility of use of ADCuh to identify the pathological type of tumor.


Description:

Magnetic resonance (MR) diffusion-weighted imaging (DWI) measures water diffusion in biological tissue. The quantification of diffusion is described by the apparent diffusion coefficient (ADC),which largely depends on the number and separation of barriers.Thus, ADC can provide information regarding tissue microstructure.

According to the literature, ADC is also related to cell membrane permeability for water molecules.It is well known that cellular water transport depends on aquaporins (AQPs).In general,the expression of aquaporins might differ in several pathologic disorders. With reference to this fact,we hypothesize that AQPs expression may influence ADC in thymic epithelial tumors(TETs).Therefore,the aim of the present study is to analyze possible associations between ADC from ultra-high b-values and AQPs expression(ADCuh) in TETs and to use ADCuh to identify the pathological type of tumor.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date May 1, 2018
Est. primary completion date January 1, 2018
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- no use of corticosteroid drugs;

- no MRI contraindication;

- no infection or fever;

- tumor diameter is greater than 2cm.

Exclusion Criteria:

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Tang-Du Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Different DWI parameters in thymic epithelial tumors 6 months
Secondary To acquire aquaporins expression level of thymic epithelial tumors 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05446935 - Intrathoracic Chemotherapy for TETs With Pleural Spread or Recurrence N/A
Not yet recruiting NCT06200233 - Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor Phase 2
Recruiting NCT04667793 - Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor Phase 2
Recruiting NCT02724696 - French National Observatory of Patients With Thymic Epithelial Tumor
Recruiting NCT05667948 - Molecular Analysis and Treatment Options of Thymic Malignancies
Recruiting NCT06421805 - Establishing Prospective Mediastinal Tumor Database of PUMCH
Recruiting NCT04522687 - Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer
Recruiting NCT04417660 - Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma Phase 2
Not yet recruiting NCT04517539 - Abscopal Effect of SBRT in Combination With rhGM-CSF and INF-α 2b for Metastatic Thymic Epithelial Tumors Phase 2
Recruiting NCT06301945 - Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors
Recruiting NCT05104736 - PT-112 in Subjects With Thymoma and Thymic Carcinoma Phase 2
Recruiting NCT03858582 - neoadjuvant_thymic Epithelial Tumor Phase 2
Recruiting NCT06311955 - Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor Phase 2